Pacira to Report 2025 Financial Results on Thursday February 26, 2026

Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading player in the development of innovative, non-opioid pain treatments, is set to announce its financial results for the fourth quarter and the full year ended December 31, 2025, on Thursday, February 26, 2026, after U.S. market hours. Following the results release, Pacira will host a live conference call and webcast at 4:30 p.m. ET, offering participants the opportunity to engage during a question and answer session. Interested attendees can pre-register to receive details for dial-in, while a live audio stream of the conference call will also be available on Pacira's investor relations website. For those unable to listen live, a replay will be accessible for approximately two weeks post-call.

Pacira continues to spearhead advancements in non-opioid pain management with three key commercial products: EXPAREL®, a long-acting local analgesic for post-surgical pain management; ZILRETTA®, an extended-release injectable for osteoarthritis knee pain; and iovera®º, a device utilizing cold therapy for effective pain control. The company is also developing a pipeline of clinical-stage products aimed at treating musculoskeletal pain, including its lead candidate, PCRX-201, a gene therapy for knee osteoarthritis currently in Phase 2 trials.

The forthcoming financial results will provide critical insights into Pacira's performance and strategic developments over the past year, as the company remains dedicated to transforming the lives of patients through innovative treatment options. Investors and stakeholders are encouraged to tune in for valuable updates on Pacira's operational progress and future direction. For further information, visit Pacira's website at www.pacira.com.

As Pacira BioSciences, Inc. (Nasdaq: PCRX) prepares to release its fourth quarter and 2025 financial results on February 26, 2026, investors should take a measured and strategic approach to the stock. Pacira, recognized as a leader in developing non-opioid pain management solutions, has a solid product lineup including EXPAREL®, ZILRETTA®, and iovera®º. Furthermore, the advancement of its pipeline assets, notably the Phase 2 candidate PCRX-201 for osteoarthritis, emphasizes its commitment to innovation in pain management.

Investors should closely monitor key performance indicators such as revenue growth from the existing product portfolio and the progress of clinical trials. The quarterly earnings call will provide valuable insights on management's expectations and operational updates that could influence the stock price. Analysts will likely scrutinize year-over-year revenue comparisons, gross margins, and any updates related to the commercialization of its innovative therapies.

Given the rising concerns surrounding opioid prescriptions and regulatory scrutiny, Pacira's non-opioid offerings tap into a growing market demand for safer pain management alternatives. However, competition is intensifying, with other pharmaceutical and biotechnology firms developing similar treatments, making it crucial for Pacira to demonstrate continued innovation and market penetration.

Should the results reflect strong sales or positive developments in clinical trials, it could create upward momentum in the stock. Conversely, any disappointing news may trigger a sell-off. Consequently, investors may find it prudent to adopt a wait-and-see strategy post-earnings report, potentially capitalizing on any volatility in the stock price. Overall, staying informed about industry trends and the outcomes of the upcoming conference call will be essential for making informed investment decisions regarding Pacira.